Valion Bio announces government-funded study of Entolimod for intestinal injury

VBIO Valion Bio Inc

$2.38 -4.03%

View chart & analysis →

1. 1Valion Bio (VBIO) announced that AFRRI, under an NIAID contract, will conduct a government-funded evaluation of Entolimod for radiation-induced intestinal injury
2. 2Entolimod delivery and IACUC approval have been completed, with the safety study launching this week and topline results from the efficacy study expected in early fall
3. 3The efficacy study, using post-exposure administration, will assess survival and recovery of intestinal tissue, and if successful, could contribute to preparedness for mass-casualty radiation events

Source ACCESSWIRE +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →